Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen

NCT03771820 is registered in ClinicalTrials.gov with NanoCarrier Co., Ltd. as lead sponsor.

NCT NCT03771820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03771820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen
Lead sponsor
NanoCarrier Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2019
Completion date
April 30, 2022
Enrollment
136 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

scchn